Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.
3.

Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.

Pouniotis DS, Esparon S, Apostolopoulos V, Pietersz GA.

Immunol Cell Biol. 2011 Nov;89(8):904-13. doi: 10.1038/icb.2011.13.

PMID:
21383765
4.
5.

Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.

Hu HM, Winter H, Urba WJ, Fox BA.

J Immunol. 2000 Oct 15;165(8):4246-53.

6.

Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines.

Ronchetti A, Rovere P, Iezzi G, Galati G, Heltai S, Protti MP, Garancini MP, Manfredi AA, Rugarli C, Bellone M.

J Immunol. 1999 Jul 1;163(1):130-6.

7.

Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies.

Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, Dagnaes F, Dembic Z, Lauritzsen GF.

Eur J Immunol. 1995 Nov;25(11):3079-86.

PMID:
7489746
8.

Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process.

Preynat-Seauve O, Contassot E, Schuler P, Piguet V, French LE, Huard B.

Cancer Res. 2007 May 15;67(10):5009-16.

9.

Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.

Peng L, Kjaergaard J, Plautz GE, Weng DE, Shu S, Cohen PA.

J Immunol. 2000 Nov 15;165(10):5738-49.

10.

NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.

Stober D, Jomantaite I, Schirmbeck R, Reimann J.

J Immunol. 2003 Mar 1;170(5):2540-8.

11.

Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes.

Oizumi S, Strbo N, Pahwa S, Deyev V, Podack ER.

J Immunol. 2007 Aug 15;179(4):2310-7.

12.

The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice.

Lyman MA, Nugent CT, Marquardt KL, Biggs JA, Pamer EG, Sherman LA.

J Immunol. 2005 Mar 1;174(5):2563-72.

13.

Memory-like CD8+ and CD4+ T cells cooperate to break peripheral tolerance under lymphopenic conditions.

Le Saout C, Mennechet S, Taylor N, Hernandez J.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19414-9. doi: 10.1073/pnas.0807743105.

14.

A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection.

Morris EC, Tsallios A, Bendle GM, Xue SA, Stauss HJ.

Proc Natl Acad Sci U S A. 2005 May 31;102(22):7934-9.

15.
16.

Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.

Chung Y, Chang JH, Kim BS, Lee JM, Kim HY, Kang CY.

Eur J Immunol. 2007 Jun;37(6):1453-62.

17.

Copresentation of intact and processed MHC alloantigen by recipient dendritic cells enables delivery of linked help to alloreactive CD8 T cells by indirect-pathway CD4 T cells.

Sivaganesh S, Harper SJ, Conlon TM, Callaghan CJ, Saeb-Parsy K, Negus MC, Motallebzadeh R, Bolton EM, Bradley JA, Pettigrew GJ.

J Immunol. 2013 Jun 1;190(11):5829-38. doi: 10.4049/jimmunol.1300458.

18.
19.

IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.

Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ.

J Immunol. 2003 Nov 15;171(10):5051-63.

20.

Role of CD4+ and CD8+ T cells in allorecognition: lessons from corneal transplantation.

Boisgérault F, Liu Y, Anosova N, Ehrlich E, Dana MR, Benichou G.

J Immunol. 2001 Aug 15;167(4):1891-9.

Items per page

Supplemental Content

Support Center